IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1252.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 1-Oct-2014
Neurobiology of Disease
Medical discovery first step on path to new painkillers
A major medical discovery by scientists at the University of Nottingham could lead to the development of an entirely new type of painkiller.
Wellcome Trust, Diabetes UK, British Heart Foundation, Richard Bright VEGF Research Fund

Contact: Emma Thorne
emma.thorne@nottingham.ac.uk
44-115-951-5793
University of Nottingham

Public Release: 1-Oct-2014
Cancer Research
Immunotherapy could stop resistance to radiotherapy
Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment.
Cancer Research UK, MedImmune

Contact: Simon Shears
simon.shears@cancer.org.uk
44-203-469-8054
Cancer Research UK

Public Release: 1-Oct-2014
PLOS One
New molecule fights oxidative stress; May lead to therapies for cancer and Alzheimer's
Breathing oxygen helps the body create energy for its cells. As a result of the breathing process, reactive molecules called 'free radicals' are produced that often cause damage to proteins and genes found in cells. This damage is known as oxidative stress. Free radicals also have been linked to cancer, Alzheimer's and Parkinson's disease. Now, investigators at the University of Missouri have discovered a molecule that treats oxidative stress.

Contact: Jeff Sossamon
sossamonj@missouri.edu
573-882-3346
University of Missouri-Columbia

Public Release: 1-Oct-2014
ACS Nano
'Stealth' nanoparticles could improve cancer vaccines
Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven't worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. And the key, they report in the journal ACS Nano, is in the vaccine's unique stealthy nanoparticles.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 1-Oct-2014
Science Signaling
Eighty percent of bowel cancers halted with existing medicines
An international team of scientists has shown that more than 80 percent of bowel cancers could be treated with existing drugs. The study found that medicines called 'JAK inhibitors' halted tumor growth in bowel cancers with a genetic mutation that is present in more than 80 per cent of bowel cancers. Multiple JAK inhibitors are currently used, or are in clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood cancers and myeloproliferative disorders.
Ludwig Cancer Research, Australian National Health and Medical Research Council, Cancer Council Victoria, Royal Melbourne Hospital, Victorian Government

Contact: Alan Gill
gill.a@wehi.edu.au
61-393-452-719
Walter and Eliza Hall Institute

Public Release: 1-Oct-2014
Journal of Nuclear Medicine
FDG-PET/CT shows promise for breast cancer patients younger than 40
Researchers at Memorial Sloan Kettering found that PET/CT imaging of patients younger than 40 who were initially diagnosed with stage I–III breast cancer resulted in change of diagnosis. As reported in the October issue of The Journal of Nuclear Medicine, while guidelines recommend FDG-PET/CT imaging only for women with stage III breast cancer, it can also help physicians more accurately diagnose young breast cancer patients initially diagnosed with earlier stages of the disease.

Contact: Kimberly Brown
kbrown@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 1-Oct-2014
Neuro-Oncology
Researchers find promise in new treatments for GBM
Glioblastma multiforme is one of the most lethal primary brain tumors, with median survival for these patients only slightly over one year. Researchers at Boston University School of Medicine, in collaboration with researchers from the City of Hope, are looking toward novel therapeutic strategies for the treatment of GBM in the form of targeted therapies against a unique receptor, the interleukin-13 receptor α chain variant 2.
Roger Williams Medical Center Brain Tumor Research Fund

Contact: Gina DiGravio
ginad@bu.edu
617-638-8480
Boston University Medical Center

Public Release: 1-Oct-2014
Journal of Pathology
UMN research pinpoints microRNA tied to colon cancer tumor growth
Researchers at the University of Minnesota have identified microRNAs that may cause colon polyps from turning cancerous. The finding could help physicians provide more specialized, and earlier, treatment before colon cancer develops. The findings are published today in The Journal of Pathology.
Department of Surgery, University of Minnesota Medical School

Contact: Caroline Marin
crmarin@umn.edu
612-624-5680
University of Minnesota Academic Health Center

Public Release: 1-Oct-2014
Journal of Interferon & Cytokine Research
A new target for controlling inflammation? Long non-coding RNAs fine-tune the immune system
Regulation of the human immune system's response to infection involves an elaborate network of complex signaling pathways that turn on and off multiple genes. The emerging importance of long noncoding RNAs and their ability to promote, fine-tune, and restrain the body's inflammatory response by regulating gene expression is described in a Review article in Journal of Interferon & Cytokine Research.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 30-Sep-2014
Oncotarget
First mapping that reveals the molecular pathway for MDSC cancer progression
InSilico Medicine and partners establish a map for cancer progression induced by MDSCs, and a means to extinguish them.
Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology

Contact: Michael Petr
michael.petr@insilicomedicine.com
InSilico Medicine, Inc.

Public Release: 30-Sep-2014
Health Technology Assessment
Genetic test would help 'cut bowel cancer spread'
Screening families of patients with bowel cancer for a genetic condition would cut their risk of developing bowel, womb, and ovarian cancers, new research has found.
National Institute for Health Research

Contact: Chris Jones
jonesc83@cardiff.ac.uk
Cardiff University

Public Release: 30-Sep-2014
British Journal of Cancer
Targeted treatment could halt womb cancer growth
A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer.

Contact: Emily Head
emily.head@cancer.org.uk
44-203-469-6189
Cancer Research UK

Public Release: 30-Sep-2014
Journal of General Internal Medicine
Endoscopists recommend frequent colonoscopies, leading to its overuse
A retrospective study led by researchers at Brigham and Women's Hospital, has found an overuse of colonoscopies for colorectal cancer screening and surveillance. The study demonstrated that endoscopists commonly recommended shorter follow-up intervals than established guidelines support, and these recommendations were strongly correlated with subsequent colonoscopy overuse.
NIH/National Cancer Institute

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-525-6383
Brigham and Women's Hospital

Public Release: 30-Sep-2014
Angewandte Chemie International Edition
Cancer therapy: Driving cancer cells to suicide
Researchers of Ludwig-Maximilians-Universitaet in Munich report that a new class of chemical compounds makes cancer cells more sensitive to chemotherapeutic drugs. They have also pinpointed the relevant target enzyme, thus identifying a new target for anti-tumor agents.

Contact: Luise Dirscherl
presse@lmu.de
49-982-180-3423
Ludwig-Maximilians-Universität München

Public Release: 30-Sep-2014
JAMA
Medical professional liability claims and esophageal cancer screening
An analysis of liability claims related to esophageal cancer screening finds that the risks of claims arising from acts of commission -- complications from screening procedure -- as well as acts of omission -- failure to screen -- are similarly low, according to a study in the Oct. 1 issue of JAMA.

Contact: Shantell Kirkendoll
smkirk@umich.edu
734-764-2220
The JAMA Network Journals

Public Release: 30-Sep-2014
Proceedings of the National Academy of Sciences
New discovery approach accelerates identification of potential cancer treatments
Researchers at the University of Michigan have described a new approach to discovering potential cancer treatments that requires a fraction of the time needed for more traditional methods.
Life Sciences Institute's Innovation Partnership

Contact: Laura Williams
laurajw@umich.edu
734-615-4862
University of Michigan

Public Release: 30-Sep-2014
New England Journal of Medicine
NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer
In this multi-center study of 50 patients with advanced non-small cell lung cancer testing positive for ROS1 gene rearrangement, the response rate was 72 percent, with 3 complete responses and 33 partial responses. Median progression-free survival was 19.2 months.
NIH/National Cancer Institute

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 30-Sep-2014
Thyroid
New guidelines for treatment of hypothyroidism endorse current therapy
Levothyroxine is considered the gold standard therapy for an underactive thyroid gland, and a new review of therapies for the condition -- including combining levothyroxine with another agent -- has not altered that assessment, say a team of investigators.Their analysis, published as a set of guidelines in the journal Thyroid (available free online), finds insufficient consistent data exist to recommend a change in use of levothyroxine -- whether generic, or sold under various trade names, such as Synthroid -- as the only drug needed to treat hypothyroidism.
National Institutes of Health

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 30-Sep-2014
2014 IEEE International Ultrasonics Symposium
'Virtual breast' could improve cancer detection
Scientists have developed a 'virtual breast' to help train clinicians in the use of ultrasound elastography. The advanced imaging technique holds promise for improving cancer detection, but only if the results are interpreted properly.
National Cancer Institute

Contact: Jennifer Donovan
jbdonova@mtu.edu
906-487-4521
Michigan Technological University

Public Release: 30-Sep-2014
FASEB Journal
New blood test determines whether you have or are likely to get cancer
A new research report published in the October 2014 issue of the FASEB Journal may make early detection and the risk assessment of cancer as easy as a simple blood test.

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology

Public Release: 30-Sep-2014
Thyroid
New hypothyroidism treatment guidelines from American Thyroid Association
Levothyroxine (L-T4), long the standard of care for treating hypothyroidism, is effective in most patients, but some individuals do not regain optimal health on L-T4 monotherapy. An expert task force of the American Thyroid Association on thyroid hormone replacement reviewed the latest studies on L-T4 therapy and on alternative treatments to determine whether a change to the current standard of care is appropriate, and they present their recommendations in an article published in Thyroid.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 30-Sep-2014
Journal of General Internal Medicine
Americans undergo colonoscopies too often, study finds
Colonoscopies are a very valuable procedure by which to screen for the presence of colorectal cancer. However, it seems that healthy Americans who do undergo this sometimes uncomfortable examination often have repeat screenings long before they actually should. Gina Kruse of Massachusetts General Hospital in the US and colleagues advise that endoscopists stick to the national guidelines more closely. Their findings appear in the Journal of General Internal Medicine, published by Springer.
National Cancer Institute, Health Resources and Services Administration, Ryoichi Sasakawa Fellowship Fund

Contact: Joan Robinson
joan.robinson@springer.com
49-622-148-78130
Springer

Public Release: 30-Sep-2014
Health Technology Assessment
Genetic test for cancer patients could be cost-effective and prevent further cases
Screening for a genetic condition in younger people who are diagnosed with bowel cancer would be cost-effective for the British National Health Service and prevent new cases in them and their relatives, new research has concluded.
National Institute for Health UK

Contact: Louise Vennells
l.vennells@exeter.ac.uk
0044-139-272-2062
University of Exeter

Public Release: 29-Sep-2014
Journal of Agricultural and Food Chemistry
New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes
University of Illinois scientists have found compounds that boost liver detoxification enzymes nearly fivefold, and they've found them in a pretty unlikely place -- the crushed seeds left after oil extraction from an oilseed crop used in jet fuel.
US Department of Agriculture

Contact: Phyllis Picklesimer
p-pickle@illinois.edu
217-244-2827
University of Illinois College of Agricultural, Consumer and Environmental Sciences

Public Release: 29-Sep-2014
Molecular Cancer Therapeutics
Transplant drug could boost the power of brain tumor treatments, U-M study finds
Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. New research suggests that the same drug could help brain tumor patients by boosting the effect of new immune-based therapies.
National Institutes of Health, University of Michigan, Phase One Foundation

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System

Showing releases 1-25 out of 1252.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases

     

 

EurekAlert!